.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The progression of prostate cancer to a castration-resistant state (CRPC) remains a significant clinical challenge for urologists globally. Resistance to second-generation androgen receptor (AR) antagonists often involves the reactivation of signaling pathways. Specifically, enzalutamide resistance prostate cancer frequently stems from increased intratumoral androgen synthesis. Researchers recently identified GPR133, an adhesion G protein-coupled receptor, as a novel membrane androgen receptor. Its role in prostate malignancy, however, was previously unknown.
A recent study published in Prostate reveals that GPR133 acts as a potent tumor suppressor. Analysis of patient-derived tissues shows that GPR133 expression is significantly lower in cancerous tissue compared to benign samples. Moreover, expression levels drop further as the disease progresses to CRPC. Low GPR133 levels correlate strongly with poorer disease-free survival. Consequently, the loss of this receptor serves as a critical event in therapeutic failure.
Mechanistically, the loss of GPR133 transcriptionally upregulates key enzymes in the steroid hormone biosynthesis pathway. The most notable enzyme is HSD3B1. This upregulation leads to elevated intracellular testosterone levels. Furthermore, these increased androgen levels sustain AR signaling despite enzalutamide treatment. Therefore, the tumor effectively bypasses the drug's inhibitory effects by producing its own fuel.
The research also demonstrates that silencing HSD3B1 can reverse the resistance induced by GPR133 knockdown. Additionally, overexpressing GPR133 can sensitize cancer cells to enzalutamide. These findings suggest that GPR133 could serve as both a valuable prognostic biomarker and a potential therapeutic target. In contrast to current treatments, targeting this pathway might prevent the metabolic adaptations that lead to enzalutamide resistance prostate cancer.
GPR133 functions as a tumor suppressor and a membrane androgen receptor. Its loss promotes the progression to castration-resistant prostate cancer and drives resistance to therapies like enzalutamide.
HSD3B1 is a key enzyme in the steroid biosynthesis pathway. When upregulated due to GPR133 loss, it increases intratumoral testosterone production, allowing cancer cells to maintain growth signaling even during treatment.
Experimental models suggest that silencing the HSD3B1 enzyme or restoring GPR133 expression can resensitize prostate cancer cells to enzalutamide treatment.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Wei L et al. Loss of GPR133 Promotes Enzalutamide Resistance in Prostate Cancer by Upregulating HSD3B1 and Intratumoral Androgen Synthesis. Prostate. 2026 Feb 10. doi: 10.1002/pros.70138. PMID: 41664980.
Hearn JWD et al. HSD3B1 and resistance to castration-resistant prostate cancer therapies. J Clin Invest. 2023;133(22):e165718.
Yuan X, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011;18(3):R45-59.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Study identifies GPR133 loss as a key mechanism driving enzalutamide resistance in prostate cancer via HSD3B1 upregulation and androgen synthesis....
6 months ago
A Bayesian network meta-analysis evaluated non-surgical treatments for benign thyroid nodules, finding thermal ablation techniques like laser and radiofrequency ablation superior in nodule volume reduction, whereas levothyroxine showed the strongest TSH suppression without significant changes in FT3 or FT4.
Today
A retrospective study demonstrates that deep learning models using longitudinal digital breast tomosynthesis significantly enhance 5-year breast cancer risk prediction compared to single-timepoint imaging and clinical models.
Today
Researchers developed poly(trimethylene carbonate)-based polymersomes loaded with L-arginine for ROS-triggered nitric oxide release. This mild, stable nano-delivery system produces gas in response to hydrogen peroxide, offering a promising, targeted platform for cardiovascular, surgical, and oncological therapy.
Today
Researchers developed a Haversian-inspired composite scaffold that addresses delayed vascularization and wet-state mechanical deterioration in critical bone defect repair. By integrating spatially programmed calcium phosphate minerals and selective silica reinforcement, the design promotes vascularized bone repair.
Yesterday
A landmark study analyzing over 56,000 adult health records in Delhi-NCR reveals that hypertension and diabetes coexistence affects nearly 5% of adults. The prevalence doubles expected rates and rises sharply after age 40. Early integrated screening is essential to prevent microvascular and macrovascular complications.
Today
